The long-term effect of quetiapine (Seroquel (TM)) monotherapy on weight in patients with schizophrenia

INTRODUCTION: Quetiapine (Seroquel(TM)) is an atypical antipsychotic drug w ith demonstrated efficacy and tolerability. In particular, placebo-level ex trapyramidal symptoms (EPS) across the entire dose range and a low propensi ty to cause sexual dysfunction suggest it,nay be associated with greater pa tient acceptability than alternative treatments,. However,er, other side-ef fects, such as weight gain, may also have a significant impact on treatment acceptability. METHOD: We report the long-term weight changes observed in a cohort of 427 patients with schizophrenia from controlled and open-label extension (OLE) trials, in which quetiapine (mean dose 475 mg/day after 1 year) was the onl y antipsychotic medication during the OLE period. RESULTS: In these patients, there was no overall effect on weight across th e body mass index (BMI) spectrum. There were no nose-related effects on wei ght, and only one patient withdrew front treatment due to an adverse event of weight gain. Quetiapine appeared to have a weight-neutral or 'normalizin g' effect, with a tendency towards favourable shifts in bodyweight in under weight patients (BMI<18.5 kg/m(2)) and severely obese patients (BMI<greater than or equal to>35 kg/m(2)). CONCLUSION: These results indicate that long-term weight changes with queti apine monotherapy are minimal and potentially beneficial, and do not appear to raise the medical concerns associated with some other atypical agents.